Effect of Empagliflozin on clinical and echocardiographic parameters in patient with reduced LVEF heart failure

Phase 3

Not yet recruiting

• Conditions: Heart failre with reduced EF(ejection fraction).; Heart failure

• Registration Number: IRCT20210809052117N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Age: 18 yr_80 yr
Heart failure with reduced EF <40%
Nondiabetic
Stable symptom and therapy for heart failure

Exclusion Criteria

Cardiovascular event, admission for cardiovascular or renal complications within last 3 months
Cancer or life-threatening condition
Estimated GFR < 45 ml/min/m2
Systolic blood pressure < 90mmhg
Pregnancy or lactating women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Echocardiography index. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Echocardiography.;Quality of life. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Kansas questionnaire.;Physical activity. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: NYHA Class and 6-MWT.

Secondary Outcome Measures

Name	Time	Method
Renal function. Timepoint: The beginning of the study and 8 weeks after start of empagliflozin. Method of measurement: Creatinine measuring and computing Glomerular Filtration Rate.;Cardiac mortality. Timepoint: During the study. Method of measurement: Follow up.;Myocardial Infurction. Timepoint: During the study. Method of measurement: Follow up.;Duration of hospitalization for cardiac causes. Timepoint: During the study. Method of measurement: Follow up.